30 years ago Prof John Hardy set out the amyloid cascade hypothesis, giving the foundation for our current understanding of Alzheimer’s.
Mike Oldham has joined Alzheimer’s Research UK as our new Director of EDoN. We caught up with Mike to find out more about his background and the work he will be doing at Alzheimer’s Research UK. What has been your career path to date? I’m an aeronautical engineer by training, spending the first part…
Today is a historic day for dementia research with the US Food and Drug Administration (FDA) announcing the first (conditional) licence of a new drug for Alzheimer’s disease in a generation.
At Alzheimer’s Research UK, we are committed to finding treatments that slow or stop the diseases that cause dementia.
We won’t stop until we find them.
When someone receives a diagnosis of dementia, little is known about how their condition will progress and affect that individual over time. This is because dementia affects every person differently, with a number of factors influencing progression such as having other health conditions, our level of cognitive reserve and whether a person takes medications to treat other conditions.
More than a quarter of us own and use a wearable device. But what if some of the data they’re collecting could help scientists identify who was in the very early stages of a disease like Alzheimer’s, even before symptoms show?
It turns out that risk genes are a really important piece of the puzzle that helps us build our understanding of how a disease progresses.
Despite delays in recruitment to face-to-face dementia research studies, volunteer enrolment onto studies hosted by Join Dementia Research is at an all-time high since the service launched in 2015.
Alzheimer’s Research UK recently awarded a £96,000 grant to Prof Kevin Morgan at the University of Nottingham to maintain and expand his large collection of DNA samples. This is to ensure he can continue his important research into the genetics of Alzheimer’s disease.